

Appendix. Tables

Table A.1 The absolute values of ctDNA of the 34 patients and CT evaluation.

Patient Number	PO ctDNA (ng/ml) days n=34	PV ctDNA (ng/ml) days n=34	SD ctDNA (ng/ml) days n=34	F1 ctDNA (ng/ml) days n=31	F2 ctDNA (ng/ml) days	F3 ctDNA (ng/ml) days	F4 ctDNA (ng/ml) days	F5 ctDNA (ng/ml) days	F6 ctDNA (ng/ml) days	LF ctDNA (ng/ml) days n=24	CT Progression days n=31
2	2.69 0	9.53 0	39.41 5	12.64 24	4.91 121	5.86 380	6.4 471	4.2 513		44.9 641	Negative 1337
3	31.1 0	18.5 0	28.3 5	19.8 17						13.2 396	Positive 585
4	3.09 0	13.08 0	21.84 6	2.95 35	5.79 160	2.6 208	1.4 273			45.02 338	Positive 152
5	5.44 0	4.7 0	62.3 6	6.9 34	6.0 390					26.9 593	Negative 1049
6	9.8 0	44.0 0	48.9 5	14.9 28	1.8 113	5.9 134	0.828 145	0.7 273	10.3 372	57.1 499	Positive 828
7	1.36 0	3.39 0	23.78 7	7.46 28	2.70 202	2.63 356	6.2 421			20.0 504	Positive 884
8	6.4 0	9.0 0	88.4 5	25.3 28	8.2 266					9.1 80	Negative 308
9	1.66 0	7.26 0	17.40 5	2.09 29	3.55 56	4.65 105	4.12 189			44.9 338	Negative 1090
10	8.8 0	17.9 0	35.0 5	18.5 25	6.0 201	4.6 390	7.5 481			25.6 537	Negative 1013
11	11.8 0	15.2 0	40.4 5	6.4 29	0.9 197	4.5 231	9.0 379			296.0 540	Negative 534
12	7.7 0	35.5 0	88.5 5	12.2 28	5.9 401	8.6 531				22.6 678	Negative 812
14	2.3 0	7.0 0	16.6 7	3.8 28	1.3 160	4.6 216	6.9 384			17.8 447	Positive 724
15	34.9 0	69.8 0	34.1 5	11.5 25							Negative 246
16	4.9 0	13.6 0	24.4 5	6.6 32	2.4 298	10.0 373				15.75 617	Negative 1154
18	8.8 0	17.6 0	46.0 12	13.40 31	6.6 158	10.3 221	4.7 324	6.0 422		56.0 541	Negative 1134
19	13.5 0	17.5 0	90.0 6	12.9 29	10.9 147	10.4 238	10.2 343			88.67 434	Negative 1049
20	3.5 0	7.9 0	9.5 5	6.2 25	6.0 184					27.45 435	Negative 1243
21	6.4 0	10.8 0	31.1 5	5.6 29							Negative 984
22	7.3 0	21.4 0	50.7 8	19.8 31	16.6 95					28.34 184	Negative 333
23	4.6 0	3.7 0	42.0 4	5.6 33	3.8 148	15.1 265				47.76 361	Positive 959
24	5.3 0	15.3 0	25.1 6	12.9 28	15.1 127	11.0 169				71.33 400	Negative 1117
25	0 0	6.9 0	29.9 4	8.3 24	41.10 94	68.80 184				58.29 327	Positive 150
27	3.6 0	14.1 0	71.2 5	8.3 35	0.8 97	0.151 167				3.4 300	Negative 969
28	4.2 0	4.2 0	12.2 4	5.5 50	8.86 129					62.13 312	Negative 995
29	3.6 0	10.2 0	14.9 5	10.9 22							Negative 243
30	6.6 0	16.0 0	78.2 5	0.2 31							Negative 263
31	3.8 0	7.5 0	35.2 7	10.2 21							Negative 303
32	5.3 0	26.0 0	10.6 0	5.2 25	0.9 184					55.84 198	Negative 890

Patient Number	PO ctDNA (ng/ml) days n=34	PV ctDNA (ng/ml) days n=34	SD ctDNA (ng/ml) days n=34	F1 ctDNA (ng/ml) days n=31	F2 ctDNA (ng/ml) days	F3 ctDNA (ng/ml) days	F4 ctDNA (ng/ml) days	F5 ctDNA (ng/ml) days	F6 ctDNA (ng/ml) days	LF ctDNA (ng/ml) days n=24	CT Progression days n=31
34	49.2 0	16.3 0	108.0 8	11.9 109							Positive 710
35	5.7 0	11.0 0	22.0 3								No CT
36	29.2 0	30.7 0	53.0 3	39.7 65							Negative 807
37	9.2 0	17.97 0	56.5 5	7.7 65	4.6 99					28.40 164	Positive 834
39	2.6 0	6.0 0	7.7 8								No CT
40	17.7 0	66 0	137.78 5								No CT
										Molecular Follow-up	Imagiology Follow-up
Mean time (days) (min; max)										413.8 (94; 678)	764.48 (150;1337)
Median time (days) (min; max)										417.0 (94; 678)	834.0 (150;1337)

Legend: **PO:** Pre-Operative; **PV:** Pulmonary Vein; **SD:** Surgical Discharge; **F1:** First Follow-up; **LF:** Last Follow-up; **ctDNA:** circulating tumour DNA; **CT:** computed tomography

Table A.2 Pairwise method analysis according to ctDNA concentration and the five time points. Significance values were adjusted using the Bonferroni correction for several tests.

	p value	p adjusted value
PO vs LF	<0.001	<0.001
PO vs F1	0.345	1.000
PO vs SD	<0.001	<0.001
PO vs PV	0.002	0.021
PV vs LF	0.001	0.014
F1 vs PV	0.046	0.464
PV vs SD	<0.001	0.001
F1 vs SD	<0.001	<0.001
LF vs SD	0.851	1.000
F1 vs LF	<0.001	<0.001

Legend: **PO:** Pre-Operative; **PV:** Pulmonary Vein; **SD:** Surgical Discharge; **F1:** First Follow-up; **LF:** Last Follow-up

Table A.3 Tumour mutational profile

Sample Nº	Histology	Mutated Gene	AA change	AF (%)
2T1	Adenocarcinoma	KRAS	p.Gly12Asp	24,0
3T1	Squamous cells	TP53	p.Ala159Ser	23,0
4T1	Squamous cells	TP53	p.Arg110Leu	52,0
5T1	Adenocarcinoma	KRAS	p.Gly12Ala	9,0
6T1	Adenocarcinoma	EGFR	p.Asp770delinsGlyTyr	27,0
7T1	Adenocarcinoma	TP53	p.Met160Ile	42,0
8T1	Squamous cells	FBXW7	p.Arg505Gly	48,0
		TP53	p.Val157Phe	53,0
9T1	Adenocarcinoma	KRAS	p.Gly12Asp	34,0
10T1	Large cell neuroendocrine	MET	p.Asn375Ser	49,0
11T1	Squamous cells	TP53	p.Arg213Leu	61,5
12T1	Adenocarcinoma	Translocation	EML4-ALK.E13A20	NA
14T1	Adenocarcinoma	EGFR	p.Leu747_Pro753delinsSer	55,8
		TP53	p.Glu171fs	46,9
		TP53	p.Glu171Gly	46,9
15T1	Adenocarcinoma	KDR	p.Gln472His	12,7
		KRAS	p.Gly12Cys	19,0
		TP53	p.Ala347Thr	4,7
		TP53	p.Gly245Cys	5,5
16T1	Adenocarcinoma	KRAS	p.Gly12Asp	13,4
		SMARCB1	p.Thr72Lys	7,3
18T1	Squamous cells	NRAS	p.Gln61Lys	4,3
		TP53	p.Ala159Val	8,7
19T1	Adenocarcinoma	Translocation	EML4-ALK.E13A20	NA
20T1	Adenocarcinoma	PIK3CA	p.Asn1044Lys	46,8
		TP53	p.Val157Phe	35,4
21T1	Adenocarcinoma	PIK3CA	p.Glu542Lys	3,4
		BRAF	p.Val600Glu	20,0
22T1	Adenocarcinoma	KRAS	p.Gly12Asp	34,6
23T1	Adenocarcinoma	No tissue		
24T1	Adenocarcinoma	Bad quality DNA for sequencing		
25T1	Adenocarcinoma	Bad quality DNA for sequencing		

27T1	Adenocarcinoma	RET	p.Cys634Tyr	3,0
		MPL	p.Ser505Asn	1,9
		MPL	p.Ala519Thr	3,4
28T1	Adenocarcinoma	CTNNB1	p.Ser37Phe	1,2
		CTNNB1	p.Ala43Val	1,5
		KIT	p.Glu561Lys	1,2
		APC	p.Arg1114Ter	1,4
		APC	p.Glu1374Lys	1,3
		EGFR	p.Leu858Arg	9,7
		SMO	p.Arg199Trp	1,6
		BRAF	p.Gly464Glu	1,4
		PTEN	p.Gly165Glu	1,5
		SMAD4	p.Gln245Ter	1,3
		SRC	p.Gln531Ter	3,9
		SMARCB1	p.Arg158Ter	1,2
29T1	Adenocarcinoma	EGFR	p.Leu747_Ala750delinsPro	8,1
		EGFR	p.Ala750Pro	7,5
30T1	Adenocarcinoma	KRAS	p.Gly12Cys	12,0
		TP53	p.Arg337Cys	4,8
31T1	Adenocarcinoma	NO MUTATION DETECTED		
32T1	Adenocarcinoma	Translocation	EML4-ALK.E13A20	NA
34T1	Adenocarcinoma	EGFR	p.Leu747_Ala750delinsPro	30,6
		EGFR	p.Ala750Pro	27,8
35T1	Adenocarcinoma	NO MUTATION DETECTED		
36T1	Adenocarcinoma	PIK3CA	p.Arg108His	1,2
		TP53	p.Thr81Ile	3,9
37T1	Adenocarcinoma	KRAS	p.Gly12Asp	15,3
		TP53	p.Trp91Ter	1,2
		TP53	p.Ala84Val	1,2
39T1	Adenocarcinoma	KRAS	p.Gly12Cys	18,6
		TP53	p.Gln136Glu	12,6
40T1	Squamous cells	TP53	p.Ile162fs	11,3